Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney

Conditions: Renal Cell Carcinoma

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 71

Sponsor: Trans Tasman Radiation Oncology Group

Location: Peter MacCallum Cancer Centre East Melbourne Victoria

Summary

This study is evaluating the activity and efficacy of Stereotactic Ablative Body Radiotherapy (SABR) for the treatment of kidney cancers.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years old * All patients must have a biopsy confirmed diagnosis of renal cell carcinoma with a single lesion within a kidney * Eastern Cooperative Oncology Group (ECOG) performance of 0-2 inclusive. * Life expectancy \> 9 months * Either medically inoperable, technically high risk for surgery or decline surgery. * Multidisciplinary decision for active treatment Exclusion Criteria: * Pre-treatment estimated glomerular filtration rate \< 30 mls/min * Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Delivery of targeted agents (such as sunitinib) are allowable only when at least 7 days separate the delivery of the proposed agent and the delivery of the stereotactic radiotherapy. * Previous high-dose radiotherapy to an overlapping region * Tumours of larger than 8cm is size

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT02613819). StuddyBuddy aggregates publicly available trial information.